Glaxo CEO: Price Pressure Continues in United States

The transcript discusses the performance and future outlook of various divisions within a pharmaceutical company. It highlights the respiratory market's challenges and the shift from Advair to new products. The consumer division is on track to achieve 20% margins, with synergies between consumer healthcare and pharmaceuticals. The oncology division is developing new products, focusing on epigenetics and immuno-oncology, with promising future prospects.

What is the expected trend for the respiratory division's growth over the full year?

• A decline in growth

• Stability with no growth

• Significant growth from Advair

• Growth driven by new products

What is the target margin percentage for the consumer division?

• 15%

• 20%

• 25%

• 30%

Why is the consumer division kept within the business despite perceived lack of synergies?

• It requires product flow from pharmaceutical owners

• It has no regulatory oversight

• It is a small, non-capital intensive business

• It operates independently from the pharmaceutical division

What area is GSK focusing on for its oncology division?

• Epigenetic and immuno-oncology

• Neurology

• Dermatology

• Cardiology

What strategic decision did GSK make regarding its old generation oncology products?

• To sell them

• To expand their production

• To rebrand them

• To merge them with new products